Scholar Rock Holding Corporation (SRRK)
NASDAQ: SRRK · Biological Products, (No Diagnostic Substances) · Cambridge, MA
Our rating: Positive
Call changed from Cautious to Positive at $46.60, moderate conviction, November 11, 2026.
Breaks if: The Positive view is broken if the lead program receives a complete-response letter from the FDA or a pivotal readout misses its primary endpoint within the next 12 months — either outcome removes the clinical-stage premium and would reprice the stock sharply. On the financial side, if the company's disclosed cash balance implies fewer than eight quarters of runway at the current $301 million annual free cash burn rate and no financing is announced within 90 days of that disclosure, the going-concern calculus shifts and the call moves to Cautious.
Key figures
| Market value | $5.9B |
|---|---|
| Revenue, last 12 months | $570000.00 |
| Net income, last 12 months | −$414M |
| Free cash flow, last 12 months | −$310M |
| Price to earnings | n/a |
| Free cash flow yield | −5.3% |
| Dividend yield | 0.0% |
| Operating margin | −71732.3% |
| Return on equity | −200.0% |
| Beta to the S&P 500 | 0.69 |
| Volatility, annualized | 238.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $570000.00 | n/a | $-0.81 | −$82M |
| June 30, 2026 | $0.00 | n/a | $-0.84 | −$70M |
| March 31, 2026 | $0.00 | n/a | $-0.83 | −$82M |
| December 31, 2025 | $0.00 | n/a | $-0.75 | −$76M |
| September 30, 2025 | $0.00 | n/a | $-0.90 | −$69M |
| June 30, 2025 | n/a | n/a | $-0.98 | −$77M |
| March 31, 2025 | n/a | n/a | $-0.67 | −$79M |
| December 31, 2024 | n/a | n/a | $-0.61 | −$50M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 3%, Gemini 1%, Mistral 2%
- Free cash flow for the quarter is above zero: Claude 4%, Gemini 1%, Mistral 3%
19 ledger entries and 36 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.